TMC207: the first compound of a new class of potent anti-tuberculosis drugs (Q24632091)

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

Europe PubMed Central

title

TMC207: the first compound of a new class of potent anti-tuberculosis drugs (English)

0 references

0 references

1 reference

Afranio Kritski

4

0 references

Alberto Matteelli

object named as

Alberto Matteelli

series ordinal

1

0 references

author name string

Anna Cc Carvalho

series ordinal

2

0 references

Kelly E Dooley

series ordinal

3

0 references

language of work or name

English

0 references

publication date

June 2010

0 references

published in

Future Microbiology

0 references

volume

5

0 references

issue

6

0 references

page(s)

849-58

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Diarylquinolines target subunit c of mycobacterial ATP synthase

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Progress of DOTS in global tuberculosis control

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

ATP synthase inhibition of Mycobacterium avium is not bactericidal

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

New tuberculosis therapeutics: a growing pipeline

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Antituberculosis drugs: ten years of research

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

New small-molecule synthetic antimycobacterials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Criteria for the control of drug-resistant tuberculosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Unorthodox approach to the development of a new antituberculosis therapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

WHO's new Stop TB Strategy

30 May 2018

1 reference

Will tuberculosis become resistant to all antibiotics?

21 January 2018

1 reference

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

21 January 2018

1 reference

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis

21 January 2018

1 reference

Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility

21 January 2018

1 reference

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

R207910 (TMC207): a new antibiotic for the treatment of tuberculosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2921705

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

28 November 2018

1 reference

12 December 2020

Conformational Analysis of R207910, a New Drug Candidate for the Treatment of Tuberculosis, by a Combined NMR and Molecular Modeling Approach

1 reference

12 December 2020

The tuberculosis X factor

1 reference

12 December 2020

Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control

1 reference

12 December 2020

Identifiers

DOI

10.2217/FMB.10.50

1 reference

1 reference

1 reference

PubMed publication ID

20521931

1 reference